<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04292249</url>
  </required_header>
  <id_info>
    <org_study_id>H-18002379</org_study_id>
    <nct_id>NCT04292249</nct_id>
  </id_info>
  <brief_title>Predictive Value of suPAR and hsCRP on Postoperative Mortality in Cardiac Surgery</brief_title>
  <official_title>Predictive Value of suPAR and hsCRP on Postoperative Mortality in 951 Patients Undergoing Elective On-pump Cardiac Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rigshospitalet, Denmark</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Persimune</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Copenhagen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Rigshospitalet, Denmark</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to investigate whether preoperative soluble urokinase plasminogen activating
      receptor (suPAR) and High-sensitivity C-Reactive Protein (hsCRP) are independent markers of
      death after cardiac surgery. Further, to assess whether suPAR and hsCRP provides increased
      predictive accuracy of the clinical risk model EuroSCORE II. The purpose of the study is to
      gain knowledge on whether these inflammatory biomarkers might be able to reveal a
      pro-inflammatory disease state that represents a significant risk in patients undergoing
      cardiovascular surgery. Hence, these biomarkers may assist clinicians in selecting
      compassionate treatment for high risk patients.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 6, 2012</start_date>
  <completion_date type="Actual">December 16, 2019</completion_date>
  <primary_completion_date type="Actual">June 11, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Association of preoperative suPAR values in relation to the censored time-to-event outcome &quot;death from any cause&quot;</measure>
    <time_frame>from index surgery to censoring date 12.31.2018</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Association of preoperative hsCRP values in relation to the censored time-to-event outcome &quot;death from any cause&quot;</measure>
    <time_frame>from index surgery to censoring date 12.31.2018</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess whether adding suPAR, hsCRP or combined suPAR+hsCRP measurements improves predictive accuracy of EuroSCORE II</measure>
    <time_frame>from index surgery to 30 days postoperative</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sensitivity of the models; EuroSCORE II, suPAR, hsCRP, suPAR+hsCRP, EuroSCOREII+suPAR, EuroSCOREII+hsCRP and EuroSCOREII+suPAR+hsCRP in relation to the time-to-event outcome &quot;death from any cause&quot;</measure>
    <time_frame>from index surgery to 30 days postoperative</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Specificity of the models; EuroSCORE II, suPAR, hsCRP, suPAR+hsCRP, EuroSCOREII+suPAR, EuroSCOREII+hsCRP and EuroSCOREII+suPAR+hsCRP in relation to the time-to-event outcome &quot;death from any cause&quot;</measure>
    <time_frame>from index surgery to 30 days postoperative</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>30 days mortality measured by a yes/no question of &quot;all-cause mortality&quot;</measure>
    <time_frame>from index surgery to 30 days</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>1-year mortality measured by a yes/no question of &quot;all-cause mortality&quot;</measure>
    <time_frame>from index surgery to 1 year</time_frame>
  </other_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">951</enrollment>
  <condition>Thoracic Surgery</condition>
  <condition>Cardiac Surgical Procedures</condition>
  <condition>Biomarkers</condition>
  <arm_group>
    <arm_group_label>Elective on-pump cardiac surgery patients</arm_group_label>
    <description>Adult patients (≥18 years) undergoing elective on-pump cardiac surgery (isolated coronary artery bypass graft (CABG), single and multiple valvular procedures, combined CABG and valvular surgery, and others).</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Blood sampling</intervention_name>
    <description>Analysis will be performed using commercially available analyses (suPARnostic® kit (validated to measure suPAR concentrations between 0.6 and 22 ng/mL) (ViroGates)). HsCRP will be measured by high sensitivity CRP assays (Tina-quant hs-CRP latex assay (validated to measure CRP concentrations between 0.3 - 20 mg/L) (Roche/Hitachi)). In patients with CRP&gt;20 mg/L a regular CRP-measurement will be performed.</description>
    <arm_group_label>Elective on-pump cardiac surgery patients</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood samples:

      The blood samples for the study were drawn preoperatively or within 24 hours of surgery and
      stored in the Persimune Biobank or two other biobanks at Dept. Cardiothoracic Anaesthesiology
      and Dept. Cardiothoracic Surgery, Rigshospitalet.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Adult patients (≥18 years) undergoing cardiac surgery at department of Cardiothoracic
        Surgery at Rigshospitalet, Copenhagen University Hospital, Denmark
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Planned elective on-pump cardiac surgery (isolated coronary artery bypass graft
             (CABG), single and multiple valvular procedures, combined CABG and valvular surgery,
             and others)

          -  Given informed consent on delivering a blood sample for the biobank.

        Exclusion Criteria:

          -  Peroperatively cancelling the surgery

          -  Sudden change to off-pump coronary artery bypass (OPCAB) surgery

          -  Death prior to surgery

          -  Project blood samples not available.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sebastian R Rasmussen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rigshospitalet, Denmark</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Cardiothoracic Anaesthesiology, Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>February 24, 2020</study_first_submitted>
  <study_first_submitted_qc>February 27, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 3, 2020</study_first_posted>
  <last_update_submitted>February 27, 2020</last_update_submitted>
  <last_update_submitted_qc>February 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 3, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Rigshospitalet, Denmark</investigator_affiliation>
    <investigator_full_name>Sebastian Roed Rasmussen</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Informed Consent Form</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>February 6, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/49/NCT04292249/Prot_ICF_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>February 6, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/49/NCT04292249/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

